The American College of Toxicology podcast program, ToxChats ©, reports on cutting-edge news in toxicological research from around the globe.
Pediatric Drug Development
Drug development targeted at pediatric populations has been the subject of a great deal of careful thought and effort by clinical and nonclinical scientists and regulators over the past 25 years. In this podcast, Dr. Judith “Judy” Henck, who is a consulting toxicologist with over 30 years of experience in the pharmaceutical industry, will be interviewed. Dr. Henck's areas of scientific expertise include developmental, reproductive, and juvenile toxicology, as well as developmental neurotoxicology. Some of the unique features of pediatric drug development and in particular focusing on nonclinical safety assessment of pharmaceuticals intended to be used in pediatric populations will be discussed.
CAR/T: New Modalities Paving the Way for Cancer
(CAR)T cells, also known as chimeric antigen receptor T cells, have transformed the landscape of cancer treatment. Instead of a standard chemotherapy, CAR-T treatment involves taking a patient's blood cells, engineering them in a lab to specifically attack cancer cells, and then injecting them back in the patient. The advent of in silico and in vitro has propelled our understanding of cancer biology and allowed us to make such leaps in cancer care. In this episode, Dr. Brian McIntosh of Covance describes these cells, how their safety or efficacy are evaluated, explains how these nontraditional precision medicines contribute to the patient’s journey and he shares his thoughts on the future of this type of cancer immunotherapy during this ACT ToxChats.
History and Risk Assessment of Vaccines—Q&A
Drs. Lisa Plitnick and Alan Stokes recently presented an ACT Signature Webinar titled “History and Risk Assessment of Vaccines: A Practical Perspective from an Immunologist and a Toxicologist.” In this podcast, Drs. Lisa Plitnick and Alan Stokes will continue to answer questions from the webinar audience including questions on vaccine development, nonclinical study design, dose selection and extrapolation, and DART requirements.
Scientific Communication: Distilling and Rehearsing to Reach Your Audience
In this episode, Dr. Nicholas Ponzio, master educator and professor of pathology, immunology, and laboratory medicine at Rutgers University's New Jersey Medical School and School of Graduate Studies and co-founder of the Rutgers Science Communication Initiative was interviewed. Dr. Ponzio discusses how he and his colleagues teach budding scientists how to communicate their cutting-edge research involving complex topics including vaccine development for the COVID-19 virus, clearly, accurately, and understandably to both general and scientific audiences.
AI and Big Data for Safety Testing
Dr. Thomas Hartung, is a professor at Johns Hopkins University and Director of the Center for Alternatives to Animal Testing. Dr. Hartung discusses some of his innovative contributions to the field of toxicology including developing advanced computer modeling systems using big data analyzed by artificial intelligence used to predict toxicity of novel compounds. Dr. Hartung gives a general overview of these concepts, and his perspective on the future of predictive modeling to supplement current toxicology research strategies. Dr. Hartung also discusses the potential for predictive modeling to expedite drug development decisions and challenges faced with introducing these technologies to regulated industries.
Shining a Light on the Science and Strategy of Phototoxicity Assessments
In this episode, Dr. Doug Learn, Director of Toxicology at Charles River Safety Assessment in Horsham, Pennsylvania, was interviewed. Dr. Learn is considered an expert in the field of phototoxicity. In this podcast, Dr. Learn shares his experiences during the evolution of how phototoxicity became a specialty field of its own, what phototoxicity means for toxicologists in the regulatory and pharmaceutical world, and how this translates to the consumer.